Familial HLH is a success story in modern medicine. Initially a disease that ... to be 4.2 cases per 1 million population in 2018 in England. 15 The annual incidence of HLH associated with cancer ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

The publication reviews the results of 204 patients with 12 tumor types enrolled and treated on the eNRGy study, concluding “Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ ...

Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

The New England Journal of Medicine has published results from the Phase II eNRGy trial for Bizengri (zenocutuzumab), a novel cancer med from Merus. Bizengri is the first approved treatment for people ...

Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin-resistant tuberculosis, according to a study published in the Jan.

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...

In Utah, patients who consent to "hormonal transgender treatment" or surgery on "sex characteristics" while they are minors ...

About 42 million people worldwide suffer from concussions each year. KYW medical editor Dr. Brian McDonough looks at a major ...

The patient has iMCD, which has a poor survival rate and few treatment options but an AI tool searched through 4,000 medications to discover one treatment which may work.

Sepsis, a life-threatening organ dysfunction, is responsible for an estimated 1 in 5 deaths globally and 1 in 3 deaths that ...